Bridgebio Pharma Stock Technical Analysis
| BBIO Stock | USD 78.18 0.06 0.08% |
As of the 3rd of February, BridgeBio Pharma shows the Mean Deviation of 1.55, downside deviation of 1.87, and Risk Adjusted Performance of 0.1416. BridgeBio Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
BridgeBio Pharma Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as BridgeBio, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to BridgeBioBridgeBio | Build AI portfolio with BridgeBio Stock |
Will Stock sector continue expanding? Could BridgeBio diversify its offerings? Factors like these will boost the valuation of BridgeBio Pharma. Projected growth potential of BridgeBio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BridgeBio Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
BridgeBio Pharma's market price often diverges from its book value, the accounting figure shown on BridgeBio's balance sheet. Smart investors calculate BridgeBio Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since BridgeBio Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between BridgeBio Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BridgeBio Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BridgeBio Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BridgeBio Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BridgeBio Pharma.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in BridgeBio Pharma on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding BridgeBio Pharma or generate 0.0% return on investment in BridgeBio Pharma over 90 days. BridgeBio Pharma is related to or competes with Revolution Medicines, Ionis Pharmaceuticals, Ascendis Pharma, Summit Therapeutics, Roivant Sciences, Moderna, and Biomarin Pharmaceutical. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases More
BridgeBio Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BridgeBio Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BridgeBio Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.87 | |||
| Information Ratio | 0.1586 | |||
| Maximum Drawdown | 12.16 | |||
| Value At Risk | (2.31) | |||
| Potential Upside | 4.23 |
BridgeBio Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BridgeBio Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BridgeBio Pharma's standard deviation. In reality, there are many statistical measures that can use BridgeBio Pharma historical prices to predict the future BridgeBio Pharma's volatility.| Risk Adjusted Performance | 0.1416 | |||
| Jensen Alpha | 0.3451 | |||
| Total Risk Alpha | 0.2523 | |||
| Sortino Ratio | 0.1773 | |||
| Treynor Ratio | 0.5421 |
BridgeBio Pharma February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1416 | |||
| Market Risk Adjusted Performance | 0.5521 | |||
| Mean Deviation | 1.55 | |||
| Semi Deviation | 1.54 | |||
| Downside Deviation | 1.87 | |||
| Coefficient Of Variation | 543.54 | |||
| Standard Deviation | 2.09 | |||
| Variance | 4.38 | |||
| Information Ratio | 0.1586 | |||
| Jensen Alpha | 0.3451 | |||
| Total Risk Alpha | 0.2523 | |||
| Sortino Ratio | 0.1773 | |||
| Treynor Ratio | 0.5421 | |||
| Maximum Drawdown | 12.16 | |||
| Value At Risk | (2.31) | |||
| Potential Upside | 4.23 | |||
| Downside Variance | 3.5 | |||
| Semi Variance | 2.37 | |||
| Expected Short fall | (1.83) | |||
| Skewness | 0.133 | |||
| Kurtosis | 1.49 |
BridgeBio Pharma Backtested Returns
BridgeBio Pharma appears to be very steady, given 3 months investment horizon. BridgeBio Pharma secures Sharpe Ratio (or Efficiency) of 0.18, which signifies that the company had a 0.18 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for BridgeBio Pharma, which you can use to evaluate the volatility of the firm. Please makes use of BridgeBio Pharma's Mean Deviation of 1.55, downside deviation of 1.87, and Risk Adjusted Performance of 0.1416 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, BridgeBio Pharma holds a performance score of 14. The firm shows a Beta (market volatility) of 0.69, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BridgeBio Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding BridgeBio Pharma is expected to be smaller as well. Please check BridgeBio Pharma's jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether BridgeBio Pharma's price patterns will revert.
Auto-correlation | 0.63 |
Good predictability
BridgeBio Pharma has good predictability. Overlapping area represents the amount of predictability between BridgeBio Pharma time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BridgeBio Pharma price movement. The serial correlation of 0.63 indicates that roughly 63.0% of current BridgeBio Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.63 | |
| Spearman Rank Test | 0.6 | |
| Residual Average | 0.0 | |
| Price Variance | 2.53 |
BridgeBio Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
BridgeBio Pharma Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of BridgeBio Pharma volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About BridgeBio Pharma Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of BridgeBio Pharma on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of BridgeBio Pharma based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on BridgeBio Pharma price pattern first instead of the macroeconomic environment surrounding BridgeBio Pharma. By analyzing BridgeBio Pharma's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of BridgeBio Pharma's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to BridgeBio Pharma specific price patterns or momentum indicators. Please read more on our technical analysis page.
BridgeBio Pharma February 3, 2026 Technical Indicators
Most technical analysis of BridgeBio help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for BridgeBio from various momentum indicators to cycle indicators. When you analyze BridgeBio charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1416 | |||
| Market Risk Adjusted Performance | 0.5521 | |||
| Mean Deviation | 1.55 | |||
| Semi Deviation | 1.54 | |||
| Downside Deviation | 1.87 | |||
| Coefficient Of Variation | 543.54 | |||
| Standard Deviation | 2.09 | |||
| Variance | 4.38 | |||
| Information Ratio | 0.1586 | |||
| Jensen Alpha | 0.3451 | |||
| Total Risk Alpha | 0.2523 | |||
| Sortino Ratio | 0.1773 | |||
| Treynor Ratio | 0.5421 | |||
| Maximum Drawdown | 12.16 | |||
| Value At Risk | (2.31) | |||
| Potential Upside | 4.23 | |||
| Downside Variance | 3.5 | |||
| Semi Variance | 2.37 | |||
| Expected Short fall | (1.83) | |||
| Skewness | 0.133 | |||
| Kurtosis | 1.49 |
BridgeBio Pharma February 3, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as BridgeBio stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 57,109 | ||
| Daily Balance Of Power | (0.02) | ||
| Rate Of Daily Change | 1.00 | ||
| Day Median Price | 78.27 | ||
| Day Typical Price | 78.24 | ||
| Price Action Indicator | (0.12) |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Will Stock sector continue expanding? Could BridgeBio diversify its offerings? Factors like these will boost the valuation of BridgeBio Pharma. Projected growth potential of BridgeBio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BridgeBio Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
BridgeBio Pharma's market price often diverges from its book value, the accounting figure shown on BridgeBio's balance sheet. Smart investors calculate BridgeBio Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since BridgeBio Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between BridgeBio Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BridgeBio Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.